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Introduction
Through the years several in vitro and in
vivo studies have indicated a protective 
effect of ginseng against development of 
disease, as well as a possible, positive effect 
on several disease states. The market for 
ginseng is greatly increasing, as it is largely 
used by both healthy individuals, as a 
nutritional supplement and by patients, often 
in combination with a prescribed drug. 
Ginseng appears to be a very difficult drug 
to investigate, for several reasons. For 
example, is it possible that a very long
duration of treatment is necessary to gain 
any long term positive effect? Furthermore
does a lot of different species of ginseng 
exist and it is possible that they each have 
very different properties. The four main 
species of ginseng are: American, Chinese, 
Korean, and Japanese. Three medical
species are currently recognised: Panax
ginseng C.A. Meyer (Korean ginseng), 
Panax japonicus C.A. Meyer (Japanese
ginseng) and Panax quinquefolius
(American ginseng) (Bahrke and Morgan, 
2000). The main constituents of ginseng 
root are the saponins or ginsenosides, which 
are glycosylated steroids and these, are the 
possible pharmacological active components
of ginseng. At least 13 saponins/ginseno-
sides have been isolated from P. ginseng
roots. These are named ginsenoside Rx,
where x is a, b1, b2, c, d, e, f, g1, g2, g3, h1, 
h2 or o according to their position on thin 
layer chromatograms (Shibata et al., 1965). 
Only two ginsenosides are common to
Japanese, Chinese, Korean and American
ginseng, namely Rg2 and Ro (Bahrke and 
Morgan, 2000). The content of each of the 
ginsenosides in a ginseng preparation varies 
a lot and probably depends on several 
factors such as the species of ginseng, 
cultivation methods, age of the plant at 
harvest (generally 6-7 years), season the 
plant is harvested (autumn is recommended
(Bahrke and Morgan, 2000)) and 
preparation of the root (for example is “red 
ginseng” the steamed and air-dried root, 
whereas “white ginseng” is the air-dried
root. Ginseng steamed at 120 oC has been 
reported to be more pharmacological active 
and have a higher content of ginsenosides 
Rg3 and Rg5 than raw ginseng (Kim et al., 
2000)). All these different factors may
complicate comparison of trials, 
investigating the efficacy of ginseng used 
for different indications. 
Recent studies indicate that it may not only 
be the root of ginseng that posses 
pharmacological activities. Lately have both 
the leaves and the berries of American
ginseng and the berries of Korean Panax
ginseng shown anti-hyperglycemic activities
in diabetic ob/ob mice (Dey et al., 2003; Xie 
et al., 2002; Xie et al., 2004b; Xie et al., 
2004a) and the berries of American ginseng 
have actually shown a more potent anti-
hyperglycemic activity than the root (Dey et 
al., 2003). And to complicate the use of 
ginseng further, have an investigation shown 
that some commercial ginseng products 
actually do not contain any true 
ginsenosides (Cui et al., 1994). Differences
in efficacy and content of ginsenosides of 
American ginseng (cultivated Panax
quinquefolius L.) depending on the batch 
have also been demonstrated (Sievenpiper et 
al., 2003a). 
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G115, marketed under the name Ginsana 
(GLP Ginsana Products SA, Lugano, 
Switzerland), is an extract of Korean Panax
ginseng that contains a standardized 
concentration of 13 ginsenosides and lately
this has been used in clinical trial set-ups of
the effects of ginseng, to overcome some of 
the above mentioned problems.
In 1999 Vogler et al. reported the results of 
a systematic review of double-blind, 
randomized, placebo-controlled clinical
trials of ginseng root extract for any 
indication (Vogler et al., 1999). Sixteen 
trials were included and actually 10 of these 
showed a significant (P<0.05), beneficial 
effect on the measured effect parameters of 
the respective trials. These effect parameters
included physical performance,
immunological parameters, psychomotor 
performance, cognitive behavior and 
reduction in blood glucose levels in type II 
diabetic patients. Four of the 16 trials 
included in the review did not show a 
significant beneficial effect of ginseng on 
physical performance, one did not show an 
effect on psychomotor performance and 
cognitive behavior and one trial did not 
show a beneficial effect on immunological 
parameters. So the evidences for an effect of 
ginseng on the mentioned indications were 
still in 1999 contradictive and the authors 
came to the conclusion that more rigorous 
investigations were needed to assess the 
possible efficacy of ginseng. 
The aim of the present review was to collect 
and report the results of more recent clinical
trials of ginseng (Panax species). The
review should allow identification of
possible interesting results or indications 
that deserve further investigation in the
future.
All identified, preferentially randomized,
placebo-controlled and blinded, clinical
studies of the use of Panax species for any 
indication, from the late 1990s to early 2005 
were included. In some areas, interesting
results of in vitro or in vivo animal studies 
were furthermore included. 
Physical and psychological 
functions
Some of the most investigated areas of the 
effects of ginseng are the influence on 
physical and psychological functions 
including effects on cognitive behavior,
mood, quality of life, prevention of stress 
and general diseases and recovery from
physical exercise. 
Cognitive performance and mood 
Several studies using animal models have 
shown improvement of cognitive functions 
like learning and memory after treatment
with ginseng (Nishijo et al., 2004; Petkov et 
al., 2003). Human studies of the effects on 
cognitive performance have yielded 
contradictory results. 
In a randomized double-blind study 
employing 112 healthy subjects above 40 
years of age, no significant difference in the 
results of psychomotor, attention, learning 
and memory tests, measured before and 
after 8-9 weeks treatment with either
placebo or 400 mg ginseng tablets (Gerimax
Ginseng Extract, Dansk Droge A/S, Ishøj, 
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Denmark. Purity and content of ginseng not 
reported), were observed (Sørensen and 
Sonne, 1996). The ginseng group did show a 
tendency to better abstract thinking and 
faster reaction times than the placebo group 
but the results were not significant. 
In a double-blind, placebo-controlled 
randomized, crossover study employing 20 
healthy subjects the effect of a single dose 
of either 0 (placebo), 200, 400 or 600 mg
ginseng extract (G115, Pharmaton SA, 
standardized to contain 4% triterpenoid 
glycosides/100 mg) on accuracy and 
responses were measured (Scholey and 
Kennedy, 2002). There was a washout 
period of 7 days between each 
treatment/study day. Scores on two 
computerized subtraction tasks were 
assessed pre-dosing and at 1, 2.5, 4 and 6 
hours after dosing. 200 mg ginseng 
significantly slowed responses at all time
points post-dosing compared to placebo, but 
it also significantly improved the accuracy 
at 4 h after dosing. 400 mg ginseng 
significantly improved accuracy at 4 and 6 h 
time points post-dosing. The crossover 
design of this study allowed each subject to 
be his or her own control. This controls for 
any possible interindividual variability that 
may influence the measured parameters. On 
the other hand it can be that the washout 
period not was long enough, which would 
lead to carryover effects in study courses 
where treatment consisted of ginseng during 
the first, second and/or third visit. 
In another randomized placebo-controlled, 
double-blind study, administering a single 
dose of 400 mg P. ginseng extract (G115, 
Pharmaton) to 20 healthy subjects, 
improvement of memory, speed and 
accuracy in different cognitive performance
tests were observed (Kennedy et al., 2002). 
Following a baseline cognitive assessment,
further test sessions took place 1, 2.5, 4, and 
6 h after the day's treatment was taken. The 
most striking effect in the study was the 
improvement in memory performance
following ginseng treatment. Ginseng 
treatment did not significantly affect mood
measured with Bond-Lader visual analogue 
scales.
A very recent study performed by the same
group as the two previously mentioned
studies, yielded similar results (Kennedy et 
al., 2004). This was a double-blind, placebo-
controlled study employing 28 healthy 
subjects. The effect of a single dose of 200 
mg ginseng extract (G115) on subjective 
mood and cognitive performance, measured 
pre-dosing and at 1, 2.5, 4 and 6 hours after 
dosing, was investigated. In comparison to 
placebo, ginseng improved the performance
in several of the cognitive performance tests 
throughout the day. No significant 
improvement of mood was observed. 
In contradiction to these three studies 
showing improved cognitive performance
after a single dose of ginseng (G115), 
another recent study found no difference in 
the scores of several memory tests, between 
a group of subjects who had been taking 
ginseng supplement (brand or types not 
reported) for 2 years or more (n=86) 
compared to age- and education-matched
control groups who had been either taking 
no supplements (n=86) or had been taking 
vitamin supplements only (n=86) (the latter 
group was included to control for possible 
effects based on general health awareness) 
(Persson et al., 2004). 
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A double-blind, randomized study has 
assessed the effects of Gericomplex
(containing 40 mg ginseng extract G115,
vitamins, minerals and trace elements) twice 
daily for 12 weeks, on quality of life and 
mood. A group of 205 healthy, employed
subjects receiving the ginseng complex were 
compared to 185 healthy, employed subjects 
who received placebo. Significantly
improved alertness, relaxation, appetite and 
overall score were observed after ginseng 
complex treatment (Wiklund et al., 1994). In 
a subgroup of the subjects with the 20% 
lowest score at baseline, the ginseng 
complex improved both vitality and 
depressed mood, indicating that subjects 
with poorest quality of life benefited the 
most from the ginseng treatment.
Another randomized placebo-controlled, 
double-blind clinical trial aimed to examine
the possible effects of ginseng on mood as 
well (Cardinal and Engels, 2001). Eighty-
three healthy young adults were randomly
assigned to receive placebo, 200 mg or 400 
mg ginseng capsules (Panax ginseng C.A. 
Meyer concentrate G115, Pharmaton Ltd, 
Lugano, Switzerland) for 60 days. Positive
affect, negative affect and total mood
disturbance were measured using different 
scaling tests, before and after the 
ginseng/placebo-intervention. No significant 
effects of ginseng were observed on positive
affect, negative affect or total mood
disturbance.
To assess the time-dependent effects of 
Panax ginseng on health-related quality of 
life (HRQOL) by use of a general health 
status questionnaire, 30 healthy young 
subjects were randomized in a double-blind 
manner to P. ginseng 200 mg/day (Ginsana) 
(n = 15) or matching placebo (n = 15) for 8 
weeks (Ellis and Reddy, 2002). The Short 
Form-36 Health Survey version 2 (SF-
36v2), a validated general health status 
questionnaire, was used to assess HRQOL at 
baseline and after 4 and 8 weeks of 
treatment. There were no significant
differences in baseline demographics and 
baseline SF-36v2 scores between the 
groups. After 4 weeks of therapy, slightly 
higher scores in social functioning (P.
ginseng 54.9+/-4.6 vs. placebo 49.2+/-6.5; P
= 0.014), mental health (P. ginseng 52.2+/-
7.7 vs. placebo 47.2+/-7.3; P = 0.075), and 
the mental component summary (P. ginseng
51.3+/-7.4 vs. placebo 44.3+/-8.3; P = 
0.019) scales were observed in subjects 
randomized to P. ginseng. These differences 
did not persist to the 8-week time point. The 
incidence of adverse effects was 33% in the 
P. ginseng group compared with 17% in the 
placebo group (P = 0.40). Subjects given P.
ginseng (58%) were more likely to state that 
they received active therapy than subjects
given placebo (17%; P < 0.05) and they 
were significantly more likely to state that 
they felt differently during treatment.
Physical performance 
Recent studies of the ability of ginseng to 
improve physical performance have not 
found evidence of any increase of for 
example maximal exercise capacity or 
positive influences on hormonal indices of
stress during exercise. Only a single study 
has found improvement of different 
pulmonary function tests and Maximal
Oxygen Consumption after ginseng 
treatment in patients with moderately-severe
Chronic Obstructive Pulmonary Disease 
(Gross et al., 2002). 
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In a placebo-controlled, double-blind 
clinical trial, thirty-one healthy young men
were randomly assigned to receive placebo 
(n=10), 200 mg (n=11) or 400 mg (n=10) 
ginseng capsules (Panax ginseng C.A. 
Meyer concentrate G115, Pharmaton Ltd, 
Lugano, Switzerland) for 60 days (Engels 
and Wirth, 1997). Submaximal and maximal
aerobic exercise responses were measured
before and after the intervention. Ginseng 
supplementation had no significant effect on 
oxygen consumption, respiratory exchange 
ratio, minute ventilation, blood lactic acid 
concentration or heart rate. 
Another group studied the effect of a 
commercially manufactured standardized
200 mg dosage of 7% Panax ginseng for 21 
days on peak aerobic exercise performance
(Allen et al., 1998). Twenty young men and 
eight young women were randomly assigned 
to ginseng (n=13) or placebo (n=15) 
treatment in a double-blind design. Physical
performance (symptom limited graded 
exercise test) on an ergometer was measured 
prior to and following treatment. No 
significant effect of ginseng treatment was 
observed for oxygen uptake, exercise time,
workload, plasma lactate or hematocrit at 
peak levels, or for heart rate. 
A randomized placebo-controlled clinical 
trial assessed the effects of Panax ginseng
(4 mL 60% ethanolic P. ginseng extract,
equivalent to 2 g/day of dried root, 
Mediherb Pty. Ltd., Warwick Queensland, 
Australia, diluted with 4 mL distilled water) 
for six weeks on competitive club-level
endurance athletes engaged in their normal
training (Gaffney et al., 2001). Sample size 
in this study was rather small as only 6 of 
the subjects receiving ginseng and 6 of those 
receiving placebo, completed the study. 
Before and after the interventions different 
measures of stress response (cortisol, 
testosterone, testosterone to cortisol ratio)
and selected markers of the immune system
status (circulating T-cells, T-helper cells
(CD4), T-suppressor cells (CD8), CD4 to 
CD8 ratio, natural killer cells and B 
lymphocytes) were measured. Neither the 
immune system variables nor the endocrine
components were changed significantly nor 
showed any clear trend from pre to post test 
in any of the two treatment groups (Gaffney
et al., 2001). 
To evaluate the effects of ginseng extract 
(G115) on Pulmonary Function Tests 
(PFTs), Maximum Voluntary Ventilation 
(MVV), Maximum Inspiratory Pressure
(MIP) and Maximal Oxygen Consumption 
(VO2max), 92 patients with moderately-
severe Chronic Obstructive Pulmonary
Disease (COPD) were randomly divided in 
groups to receive G115 100 mg (Ginsana, 
Pharmaton Ltd, Lugano, Switzerland) twice 
daily for three months (n = 49) or placebo (n 
= 43) (Gross et al., 2002). PFTs, MVV and 
MIP were studied before treatment and 
every two weeks for the 3-month-study
period. Exercise test and VO2max
measurements were performed before the 
beginning and after six weeks and three 
months. Baseline demographics and 
pulmonary parameters were similar between 
the groups. In the ginseng, but not in the 
placebo group, all parameters significantly 
increased above baseline and compared with 
the placebo group. No side effects were 
observed. It was concluded that G115 100 
mg twice daily for three months, but not 
placebo, improved PFTs, MVV, MIP and 
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VO2max in patients with moderately-severe
COPD.
In another randomized placebo-controlled, 
double-blind clinical trial, twenty-seven 
healthy young men supplemented their diet 
with placebo (n=12) or 400 mg (n=15) 
ginseng capsules (Panax ginseng C.A. 
Meyer concentrate G115, Pharmaton Ltd, 
Lugano, Switzerland equivalent to 2 g P.
ginseng C.A. Meyer root material) for 60 
days (Engels et al., 2003). The aims of the 
study were to examine the effects of 
prolonged ginseng supplements on secretory 
immunoglobin A (SIgA), physical 
performance and recovery responses of 
individuals undergoing exhausting interval 
exercise. SIgA is the primary immunoglobin
contained in secretions of the mucosal
immune system, and its levels in salivary 
fluids correlate more closely with resistance
to respiratory infections caused by certain 
viruses, than do serum antibodies or other 
immune parameters (Engels et al., 2003). 
Before and after ginseng or placebo 
intervention each subject performed three 
30-second Wingate tests interspersed with 
3-minutes recovery periods. SIgA secretion 
rate, peak and mean mechanical power 
output and exercise recovery heart rate was 
determined. Postintervention minus
preintervention change scores for SIgA 
secretion rate, exercise performance and 
recovery heart rate were similar between 
ginseng- and placebo-treated groups
(P>0.05) (Engels et al., 2003). 
Menopausal symptoms 
Very few studies of the effects of ginseng on 
menopausal symptoms have been 
performed. Because ginseng have been
reported to have estrogenic effects (Cho et 
al., 2004) and because positive effects on 
stress and mood furthermore have been 
stated, possible positive effects in 
postmenopausal women have been 
speculated. But also in this area a bit 
contradictory results have been obtained. 
The effects of 6 g Korean red ginseng (the 
root of Panax ginseng C.A. Meyer) daily for 
30 days, on the degree of psychological 
dysfunction and levels of stress hormones, 
were measured in 12 postmenopausal
women with climacteric syndromes (Tode et 
al., 1999) and the levels were compared to 
the levels of 8 postmenopausal women 
without any climacteric syndromes, who 
were not treated. Ginseng treatment
decreased the scores of psychological tests 
to normal range and significantly decreased 
the cortisol to dehydroepiandrosterone-
sulfate ratio, which are stress-related
hormones thought to be of importance for 
psychological functions such as depression 
and memory dysfunction in postmenopausal
women (Tode et al., 1999). The study had 
several limitations, which should be 
recognized; it was not randomized, blinded 
or placebo-controlled. Furthermore was the 
sample size very small and the supplier of 
the ginseng used was not stated. 
A randomized, multicenter, double-blind
study assessed the effects of 200 mg
standardized ginseng extract (Ginsana,
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G115, GLP Ginsana Products SA, Lugano, 
Switzerland) compared with those of a 
placebo on quality of life and physiological 
parameters in 384 symptomatic
postmenopausal women (Wiklund et al., 
1999). Validated questionnaires 
(Psychological General Well-Being 
(PGWB) index, Women's Health 
Questionnaire (WHQ)) and Visual Analogue 
(VA) scales were used to assess the quality
of life at baseline and after 16 weeks'
treatment with either the ginseng extract or 
placebo. The efficacy of ginseng on 
postmenopausal symptoms, physiological 
parameters (follicle-stimulating hormone
(FSH) and estradiol levels, endometrial
thickness, maturity index and vaginal pH) 
was recorded at the same time points. Of the 
384 randomized patients (mean age 53.5 +/- 
4.0 years), the questionnaires were 
completed by 193 women treated with 
ginseng and 191 treated with placebo. The 
group treated with ginseng showed only a 
tendency for a slightly better overall
symptomatic relief (P< 0.1). Exploratory 
analysis of PGWB subsets, however, 
reported P-values < 0.05 for depression, 
well-being and health subscales in favor of 
ginseng compared with placebo. No 
statistically significant effects were seen for 
the WHQ and the VA scales or the 
physiological parameters, including 
vasomotor symptoms (hot flushes). 
In a double-blind, placebo-controlled study, 
post-menopausal women aged 51-66 were 
randomly assigned to 12 weeks' treatment
with Gincosan (320 mg/day, Pharmaton SA, 
Switzerland, containing 120 mg Ginkgo 
biloba (GK501), and 200 mg Panax ginseng
(G115)) (n=30), or matched placebo (n=27) 
(Hartley et al., 2004). They were given 
measurements of mood, somatic anxiety, 
sleepiness, and menopausal symptoms and a 
battery of cognitive tests before treatment
and after 6 and 12 weeks of treatment. There 
were no significant effects of Gincosan 
treatment on ratings of mood, bodily 
symptoms of somatic anxiety, menopausal
symptoms, or sleepiness or on any of the 
cognitive measures of attention, memory or 
frontal lobe function. 
Diabetes
In the recent years several clinical studies
have shown positive effects of ginseng on 
blood glucose levels both in diabetic 
patients and healthy individuals. One study 
was published in 1995 (Sotaniemi et al., 
1995) and this study was included in the 
review by Vogler et al. from 1999 (Vogler
et al., 1999). As mentioned in the 
introduction this group found reduction in 
fasting blood glucose levels in 24 newly 
diagnosed type 2 diabetic patients after 8 
weeks treatment with 100 mg or 200 mg
ginseng (Dansk Droge, Copenhagen) 
compared with 12 patients taking placebo. 
The study was double-blinded and 
randomized. The ginseng therapies 
furthermore elevated mood and improved
psychophysical performance. The 200-mg
dose of ginseng in addition to this 
significantly improved glycated hemoglobin
(HbA1c) and serum
aminoterminalpropeptide (PIIINP). After
publication of this study several clinical 
studies on the effects of ginseng treatment
on blood glucose levels have been 
performed by a group of Canadian 
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researchers from St. Michael`s Hospital in 
Toronto:
Ten nondiabetic individuals were 
randomized to on 12 separate occasions 
receive a single dose of 0 (placebo), 3, 6 or 
9 g of ground American ginseng root 
(Panax quinquefolius L.)  at 40, 80, or 120 
minutes before a 25 g oral glucose challenge 
(Vuksan et al., 2000a). Capillary blood 
glucose was measured prior to ingestion of 
ginseng or placebo capsules and at 0, 15, 30, 
45, 60 and 90 minutes from start of 
challenge. Compared with the placebo, 3, 6 
and 9 g of ginseng reduced (P<0.05)
postprandial incremental glucose at 30, 45 
and 60 minutes; also, 3 and 9 g of ginseng 
did so at 90 minutes. The 9 g ginseng dose 
administred 60 minutes before the glucose 
challenge, reduced incremental postprandial 
glucose relative to 3 g of ginseng (P<0.05).
All ginseng doses reduced (P<0.05) area 
under the incremental glucose curve (3 g, 
26.6%; 6 g, 29.3%; 9 g, 38.5%). Ginseng 
taken at different times did not have an 
additional influence on postprandial 
glycemia. The authors conclude that in 
nondiabetic individuals, 3, 6 or 9 g of 
American ginseng taken 40, 80 or 120 
minutes before a glucose challenge similarly
improved glucose tolerance. 
In another study 10 nondiabetic subjects and 
9 subjects with type 2 diabetes mellitus were 
randomized, on 4 separate occasions with 
minimum one weeks washout between each 
visit, to receiving 3 g American ginseng 
(Panax quinquefolius L.) or placebo 
capsules, either 40 minutes before or 
together with a 25-g oral glucose challenge 
(Vuksan et al., 2000b). A capillary blood 
sample was taken fasting and then at 15, 30, 
45, 60, 90, and 120 (only for subjects with 
type 2 diabetes mellitus) minutes after the 
glucose challenge. In nondiabetic subjects, 
no differences were found in postprandial 
glycemia between placebo and ginseng 
when administered together with the glucose 
challenge. When ginseng was taken 40 
minutes before the glucose challenge, 
significant reductions in area under the 
glycemic curve (18%+/-31%) were observed 
(P<0.05). In subjects with type 2 diabetes 
mellitus, significant reductions in area under 
the glycemic curve were observed both 
when ginseng was taken 40 minutes before 
(19%+/-22%) and together (22%+/-17%) 
with the glucose challenge (P<0.05).
In a similar study were ten type 2 diabetic 
patients (6 men, 4 women) randomly
administered 0 g (placebo) or 3, 6, or 9 g 
ground American ginseng (Panax
quinquefolius L.) root in capsules (Ontario-
grown ground root of American ginseng, 
Chai-Na-Ta Corp., British Columbia,
Canada) at 120, 80, 40, or 0 min before a 
25-g oral glucose challenge (Vuksan et al., 
2000c). Capillary blood glucose was 
measured before ingestion of ginseng or 
placebo and at 0, 15, 30, 45, 60, 90, and 120 
min from the start of the glucose challenge. 
Two-way analysis of variance (ANOVA) 
demonstrated that treatment (3, 6, and 9 g 
ginseng) but not time of administration
(120, 80, 40, or 0 min before the challenge) 
significantly affected postprandial glycemia
(PPG) (P<0.05), with significant (P = 0.037) 
interaction for area under the curve (AUC). 
Pairwise comparisons showed that 
compared with 0 g (placebo), 3, 6, or 9 g 
significantly (P<0.05) reduced AUC 
(19.7%, 15.3%, and 15.9%, respectively) 
and incremental glycemia at 30 min (16.3%, 
18.4%, and 18.4%, respectively), 45 min
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(12.5%, 14.3%, and 14.3%, respectively), 
and 120 min (59.1%, 40.9%, and 45.5%, 
respectively). However, pairwise 
comparisons showed no differences between 
the 3-, 6-, or 9-g doses and any of the times
of administration. Ginseng reduced PPG 
irrespective of dose and time of 
administration. No more than 3 g ginseng 
was required at any time in relation to the 
challenge to achieve reductions in 
postprandial glycemia.
In another randomized placebo-controlled, 
single-blinded, crossover study, 12 healthy 
subjects (7 men and 5 women) received 16 
treatments: 0 (placebo), 1, 2, or 3 g 
American ginseng (Panax quinquefolius L.
3-year-old Ontario dried and ground ginseng 
root provided by Chai-Na-Ta Corp., 
Langley, Canada) at 40, 20, 10, or 0 min
before a 25-g oral glucose challenge 
(Vuksan et al., 2001a). A minimum of 3 
days separated each visit to minimize
carryover effects. Capillary blood was
collected before administration and at 0, 15, 
30, 45, 60, and 90 min after the start of the 
glucose challenge. Postprandial glycemia
was lower over the last 45 min of the test
after doses of 1, 2, or 3 g ginseng than after 
placebo (P < 0.05); there were no significant 
differences between doses. The reductions 
in the areas under the curve for these 3 
doses were 14.4% +/- 6.5%, 10.6% +/- 
4.0%, and 9.1% +/- 6%, respectively. 
Glycemia in the last hour of the test and area 
under the curve were significantly lower 
when ginseng was administered 40 min 
before the challenge than when it was 
administered 20, 10, or 0 min before the 
challenge (P < 0.05). The authors conclude 
that American ginseng reduced postprandial 
glycemia in subjects without diabetes. These 
reductions were time dependent but not dose 
dependent: an effect was seen only when the 
ginseng was administered 40 min before the 
challenge. Doses within the range of 1-3 g 
were equally effective. 
In a review from 2001 by the same
Canadian group, a long-term study that 
apparently has only been published as an 
abstract (American Diabetes Association 
Annual Meeting, Diabetes Suppl (1) A95, 
Abstract No. 384, 2000), is summarized
(Vuksan et al., 2001b). In this study 24 well-
controlled type 2 diabetic subjects were 
randomized to consume 1 g of a 
standardized American ginseng extract
(Panax quinquefolius L. CNT 2000 
produced by Chai-Na-Tai Corp., Langley, 
BC, Canada) or placebo before each meal
three times daily for 8 weeks while
following Canadian Diabetes Association 
diet. 17 of the subjects maintained 
antidiabetic pharmacological treatment and 
15 of the subjects maintained
antihypertensive pharmacological treatment.
Eight weeks of ginseng treatment modestly
but significantly reduced HbA1c,
significantly decreased fasting blood 
glucose (P<0.027), nonsignificantly 
increased insulin levels and significantly 
decreased blood pressure compared to 
placebo treatment. It was concluded that 
American ginseng extract added to the
conventional treatment of diabetes 
significantly improved glycaemic and blood 
pressure control beyond conventional 
treatment alone. Furthermore is a 
mechanism of action underlying American 
ginsengs hypoglycemic action proposed to 
be an enhancement of insulin secretion 
(Vuksan et al., 2001b). 
12
Another study by the Canadian group was 
using a randomized, single-blind design. 12 
healthy subjects (six males and six females)
received 6 g American ginseng (Panax
quinquefolius L. provided by Chai-Na-Ta 
Corp., BC, Canada) or placebo 40 min
before a 75 g oral glucose tolerance test 
(Sievenpiper et al., 2003a). The protocol 
followed the guidelines for the oral glucose 
tolerance test, with venous blood samples 
drawn at -40, 0, 15, 30, 45, 60, 90 and 120 
min. Ginsenosides in the ginseng were 
assessed by established methods for HPLC-
UV. Repeated measures analysis of variance
demonstrated that there was no significant 
effect of the ginseng on incremental plasma
glucose (PG) or insulin (PI) or their areas
under the curve. Indices of insulin 
sensitivity and release calculated from the 
oral glucose tolerance test were also 
unaffected. The ginseng contained 1.66% 
total ginsenosides, 0.90% (20S)-
protopanaxadiol (PPD) ginsenosides, and 
0.75% (20S)-protopanaxatriol (PPT) 
ginsenosides, with the following key ratios: 
PPD:PPT of 1.2, Rb(1):Rg(1) of 8.1, and 
Rb(2):Rc of 0.18. It was concluded that the 
used batch of ginseng was unable to 
reproduce the postprandial hypoglycemic
effects that had been observed by the group 
previously. Possible explanations for this 
discrepancy was stated to be decrements in 
total ginsenosides and the key ratios 
PPD:PPT, Rb(1):Rg(1), and Rb(2):Rc. The 
authors conclude that the data suggest that 
the ginsenoside profile of American ginseng 
might play a role in its hypoglycemic
effects, but that the involvement of other
components cannot be excluded. It should 
be noted that opposed to previous studies 
conducted by this group, the oral glucose 
tolerance test used persist of 75 g glucose 
compared to 25 g used earlier. 
The aim of one more study was to 
investigate whether Panax ginseng C.A. 
Meyer (three-year-old powdered whole root 
from Korean Ministry of Agriculture and 
Forestry, Seoul South Korea) was able to 
replicate the glycemia-lowering efficacy 
reported earlier for a batch of American
ginseng (Panax quinquefolius L.)
(Sievenpiper et al., 2003b). Two separate 
acute dose escalation studies were 
performed. Each study was conducted in a 
separate sample of 11 healthy subjects using 
a randomized, single-blind, placebo-
controlled, multiple-crossover design.
Treatments consisted of 0 (placebo), 1, 2, 
and 3 g of P. ginseng for the first study and 
0 (placebo), 3, 6, and 9 g P. ginseng for the
second study administered 40 minutes
before a 75 g oral glucose tolerance test 
protocol with blood drawn at -40, 0, 15, 30, 
45, 60, 90, and 120 minutes. A minimum of 
three days separated each visit to minimize
carry-over effects. Ginsenoside content was 
analyzed by HPLC-UV. Neither the main
effect of pooled-treatment, nor dose, nor 
either factors interaction with time was 
significant for incremental plasma glucose 
and insulin. But the diagnostically and 
therapeutically relevant two-hour plasma
glucose value was significantly higher for 
pooled P. ginseng treatment than placebo 
(5.46 +/- 0.31 versus 4.99 +/- 0.30 mmol/L,
P = 0.050). Ginsenoside analyses showed 
that the P. ginseng contained up to 96% 
lower and sevenfold higher quantities of 
various ginsenosides and their ratios than 
the previous efficacious batch of American 
ginseng. It was concluded that P. ginseng
showed both null and opposing effects on 
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indices of acute postprandial plasma glucose 
and insulin. This was in contrast to previous 
findings with American ginseng. One 
explanation may be the marked ginsenoside 
differences. Also in this study a 75 g oral 
glucose tolerance test was used but it was 
noted in the discussion that 6 g of the 
original batch of American ginseng lowered 
the plasma glucose response to a 75 g oral 
glucose tolerance test significantly (P < 
0.05) in 8 nondiabetic subjects, but 
published data from the study (presumably
from 1991) could not be found. 
The aim of yet another study by the 
Canadian group was to assess the effect of 
eight popular ginseng types on postprandial 
plasma glucose (PG) and insulin (PI) indices 
and to link the possible effects to 
ginsenoside profiles. Using a double-blind, 
randomized, multiple-crossover design, 12 
healthy participants (6 females and 6 males)
received a total of ten 3 g treatments,
consisting of: American (Panax
quinquefolius L.), American-wild (wild 
Panax quinquefolius L.),  Korean (Panax
ginseng C.A. Meyer), Korean-red (steam
treated Panax ginseng C.A. Meyer), 
Vietnamese-wild (Panax vietnemensis),
Siberian (Eleutherococcus senticus),
Japanese-rhizome (Panax japonicus C.A. 
Meyer), and Sanchi (Panax notoginseng
[Burk.] F.H. Chen) ginsengs and two 
placebos (Sievenpiper et al., 2004). Each 
treatment was given 40-minutes before a 75 
g oral glucose tolerance test with blood 
drawn at -40, 0, 15, 30, 45, 60, 90, 120-
minutes. HPLC-UV analysis quantified 
seven principal ginsenosides. Comparisons
with placebo showed a tendency for 
American ginseng and Vietnamese ginseng 
to lower 90-min-PG (P < 0.06), while 
Korean ginseng raised peak-PG and AUC-
PG, American-wild ginseng raised 120-min-
PG, and Siberian ginseng raised 90-min-PG,
120-min-PG, and AUC-PG (P < 0.05). The 
different glycemic effects of the different 
types of ginseng could however not be 
predicted wholly by differences in their 
seven principal ginsenosides. Other 
unmeasured ginsenosides or non-
ginsenoside components may as well have 
been involved. 
Lung infections 
The major cause of morbidity and mortality
in cystic fibrosis patients is chronic 
Pseudomonas aeruginosa lung infection. 
Rat and mouse models of Pseudomonas
aeruginosa lung infection mimicking that in 
patients with cystic fibrosis, treated with 
Panax ginseng C.A. Meyer (Song et al., 
1997; Song et al., 1998; Song et al., 2002; 
Song et al., 2003) have shown significantly 
milder lung pathology and modulations of 
the immune system, which may favor faster 
clearance of the bacterial infection 
compared to saline treated control groups. 
Only one publication of the ability of 
American ginseng (Panax quinquefolius L.) 
to prevent acute respiratory illness (ARI) in 
institutional settings including a nursing 
home and assisted living at three sites, has 
been found (McElhaney et al., 2004). It 
describes two randomized, double-blind, 
placebo-controlled trials conducted late in 
the 2000 (8 week) and 2000-2001 (12 week) 
influenza seasons. The participants were 
eighty-nine (2000) and 109 (2000-2001) 
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subjects, average age 81 and 83.5, 
respectively; 74% women. Approximately 
90% had received influenza vaccine. 
Ginseng extract (CVT-E002), 200 mg or 
placebo was administered orally twice a 
day. Acute respiratory illness was defined as 
two new respiratory symptoms or one with a 
constitutional symptom. Confirmation of 
viral acute respiratory illness was done by 
culture (influenza or respiratory syncytial
virus (RSV)) or serology for influenza. An 
intent-to-treat analysis of pooled data 
corrected for drug exposure time showed 
that the incidence of laboratory-confirmed
influenza illness (LCII) was greater in 
placebo- (7 cases/101 subjects) than
ginseng-treated (1/97) groups (odds ratio 
(OR)=7.73, P=0.033). Combined data for 
LCII and RSV illness were also greater in 
placebo- (9/101) than ginseng-treated (1/97) 
groups (OR=10.50, P=0.009). An overall 
89% relative risk reduction of acute 
respiratory illness in the ginseng treated 
groups was found. A bias in these studies 
could be that 90% had received influenza 
vaccine.
Cancer
A prospective cohort study was conducted 
in Kangwha-eup from August 1987 to 
December 1992 to evaluate the preventive 
effect of ginseng against cancer on a 
population residing in a ginseng cultivation 
area (Yun and Choi, 1998). 4634 people 
over 40 years of age, who completed a 
questionnaire on ginseng intake, were 
included. In an attempt to obtain detailed 
information about ginseng intake, they were 
asked to specify their age at initial intake,
frequency and duration of ginseng intake, 
the kind of ginseng, etc. Multiple logistic
regression was used to estimate relative 
risks (RR) when controlling simultaneously
for covariates. Ginseng consumers had a 
decreased risk (RR = 0.40, 95% confidence 
interval [CI]: 0.28-0.56) for developing 
cancer compared with non-consumers. On 
the type of ginseng, the RR was 0.31 (95% 
CI: 0.13-0.74) for fresh ginseng extract 
consumers and 0.34 (95% CI: 0.20-0.53) for 
consumers of multiple combinations. There 
was no cancer death among 24 red ginseng 
consumers. There was a decreased risk with 
a rise in the frequency of ginseng intake, 
showing a dose-response relationship. The 
RR of ginseng consumers were 0.33 (95% 
CI: 0.18-0.57) in gastric cancer and 0.30 
(95% CI: 0.14-0.65) in lung cancer. Among
ginseng preparations, fresh ginseng extract 
consumers were significantly associated 
with a decreased risk of gastric cancer (RR 
= 0.33, 95% CI: 0.12-0.88). The authors 
conclude that the results strongly suggest 
that Panax ginseng C.A. Meyer has non-
organ specific preventive effect against 
cancer.
In a randomized, placebo-controlled clinical 
trial red ginseng powder from Panax
ginseng C.A. Meyer was shown to inhibit 
the recurrence of stage III gastric cancer and 
to show immunomodulatory activities 
during postoperative chemotherapy, after a 
curative resection with D2 lymph node 
dissection (Suh et al., 2002). 42 patients 
were randomized to take 4.5 g ginseng per 
day or matched placebo during the first six 
months after operation. Flow cytometric
analyses for peripheral T-lymphocyte
subsets showed that ginseng restored CD4 
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levels to the initial preoperative values
during postoperative chemotherapy. 
Depression of CD3 during postoperative 
chemotherapy was also inhibited by ginseng 
ingestion. The study demonstrated a five-
year disease free survival and overall 
survival rate that was significantly higher in 
patients taking the red ginseng powder 
during postoperative chemotherapy versus 
control (68.2% versus 33.3%, 76.4% versus 
38.5%, respectively, P < 0.05). 
Hypertension
A single-blinded placebo-controlled study 
aimed to investigate the changes of diurnal 
blood pressure pattern after 8 weeks of red 
ginseng medication (4.5 g/day, Ginseng 
Radix Rubra, Korean Tobacco & Ginseng
Corporation, Taejeon, Korea. 1.5 g three 
times a day) by 24-hour ambulatory blood 
pressure monitoring (every 30 minutes from
8 A.M. to 8 A.M. the following morning)
(Han et al., 1998). 34 subjects were 
classified to 4 subgroups based on 24 hour 
ambulatory blood pressure monitoring.
Placebo was administered for 4 weeks and 
red ginseng for the following 8 weeks. 24-
hour ambulatory blood pressure monitoring
was done 1) before starting the intervention, 
2) after 4 weeks of placebo administration
and 3) after further 8 weeks ginseng 
administration. In 26 subjects with essential 
hypertension, 24 hour mean systolic blood 
pressure decreased significantly (P = 0.03) 
while diastolic blood pressure only showed 
a tendency of decline. The decreases in 
pressures were observed at daytime (8 
A.M.-6 P.M.) and dawn (5 A.M.-7 A.M.). In 
8 subjects with white coat hypertension, no 
significant blood pressure change was 
observed. The authors suggest that red 
ginseng might be useful as a relatively safe 
medication adjuvant to current 
antihypertensive medications.
The effect of 4.5 g Korean red ginseng per 
day for approximately 24 months, on 
vascular endothelial cell dysfunction in 
patients with hypertension has been 
investigated in a randomized clinical trial 
(Sung et al., 2000). Seventeen patients with 
hypertension were divided into a ginseng-
treated (7) and a non-treated (10) group and 
10 healthy subjects were included as control 
group. The ginseng treatment period was 
approximately 24 months (ranging 21-27 
months). To assess the function of the 
vascular endothelial cell, changes of forearm
blood flow to infusion of acetylcholine,
sodium nitroprusside and bradykinin in 
incremental doses, were measured by 
venous occlusion plethysmography. In the 
ginseng-treated hypertensive group, forearm
bloods flows at the highest dose of 
acetylcholine and bradykinin, were 
significantly higher than those of the non-
treated hypertensive group and were not 
different from those of the control group. In 
the case of sodium nitroprusside infusion, 
no significant differences were observed 
between the control, non-treated and treated 
groups. Based on these results it is 
speculated by the authors that Korean red 
ginseng can improve the vascular 
endothelial dysfunction in patients with
hypertension through increasing the 
synthesis of nitric oxide. 
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Miscellaneous
The efficacy of Korean red ginseng for 
erectile dysfunction using the International
Index of Erectile Function, RigiScan 
(UroHealth Systems, Laguna Niguel, 
California), hormonal levels and penile 
duplex ultrasonography with audiovisual 
sexual stimulation has also been 
investigated in a total of 45 patients with 
clinically diagnosed erectile dysfunction in a 
randomized, double-blind, placebo 
controlled, crossover study (8 weeks on 
treatment, 2 weeks of washout and 8 weeks 
on treatment) (Hong et al., 2002). The 
effects of Korean red ginseng and placebo 
were compared using multiple variables.
The ginseng dose was 900 mg 3 times daily. 
Mean International Index of Erectile 
Function scores were significantly higher in 
patients treated with Korean red ginseng 
than in those who received placebo. Scores
on questions 3 (penetration) and 4 
(maintenance) were significantly higher in 
the ginseng than in the placebo group. In 
response to the global efficacy question 60% 
of the patients answered that Korean red 
ginseng improved erection. Among other 
variables penile tip rigidity on RigiScan
showed significant improvement for ginseng 
versus placebo. The crossover design 
allowed each subject to be his own control. 
Washout period could be to short, which 
would lead to carryover effects in study
courses where treatment consisted of 
ginseng during the first period; this would 
reduce the effect observed.
In a clinical study employing eight young 
male subjects the effects of Panax ginseng
extract (2 g three times a day for 8 weeks) 
on lipid metabolism were examined by 
measuring cholesterol, malondialdehyde
(MDA), superoxide dismutase (SOD), and 
catalase (CAT) before and after intervention
(Kim and Park, 2003). ILWha Co. Ltd.,
Kyonggi, Korea supplied the ginseng extract 
and financed the study. Ginseng was 
extracted with 50% of alcohol and the 
components were characterized as follows: 
2.5% for Rb1, 2.1% for Rb2, 2.6% for Rc,
1.1% for Rd, 1.2% for Re, 0.4% for Rg1, 35 
for H2O, 7% for protein, 0.3% for lipid, 
3.5% for ash, 35% for sugar, 0.5% for 
amino acid, 0.2% for vitamin and 4% for 
others. Serum total cholesterol (TC),
triglyceride (TG), low-density lipoprotein
(LDL) and plasma MDA levels were 
decreased by administration of ginseng, 
however high density lipoprotein (HDL) 
was increased. Those results suggest that a 
possible hypolipidemic effect of ginseng 
could be associated with a decrease in TC, 
TG, LDL, MDA levels and an increase in 
HDL. Administration of ginseng increased 
SOD and CAT activities. It should be noted 
that the used sample size (8) was very small
and that the study not was placebo-
controlled and blinded. 
Drug interactions and effects on 
enzymes
In an in vitro study the effect of a 
standardized Panax ginseng extract (G115), 
a standardized Panax quinquefolius (or 
North American ginseng) extract (NAGE), 
and individual ginsenosides (Rb1, Rb2, Rc, 
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Rd, Re, Rf, and Rg1) on CYP1 catalytic 
activities, was assessed by measuring 7-
ethoxyresorufin O-dealkylation (Chang et 
al., 2002). G115 and NAGE decreased 
human recombinant CYP1A1, CYP1A2, 
and CYP1B1 activities in a concentration-
dependent manner. A striking finding was 
that NAGE was 45-fold more potent than 
G115 in inhibiting CYP1A2. Compared
with G115, NAGE also preferentially 
inhibited 7-ethoxyresorufin O-dealkylation 
activity in human liver microsomes. Rb1, 
Rb2, Rc, Rd, Re, Rf, and Rg1, either 
individually or as a mixture and at the levels 
reflecting those found in an inhibitory 
concentration (100 Pg/ml) of NAGE or 
G115, did not influence CYP1 activities. 
However, at a higher single ginsenoside 
concentration (50 Pg/ml), Rb1, Rb2, Rc, Rd, 
and Rf inhibited these activities.
To investigate the possible effect of ginseng 
on the urinary excretion of the 6-beta-
hydroxycortisol/cortisol ratio as a marker of 
cytochrome P450 (CYP) 3A enzyme
induction, twenty subjects received Panax
ginseng 100 mg standardized to 4% 
ginsenosides twice daily for 14 days 
(Anderson et al., 2003). Panax ginseng did 
not significantly alter the urinary 6-beta-
OH-cortisol/cortisol ratio, suggesting that 
unlike St. John's wort, P. ginseng is not a 
CYP3A inducer. 
In another in vitro study, ginsenoside Rb1, 
Rb2, Rc, and Rd (from Idofine Chemical
Co. Sommerville, NJ) at various 
concentrations (0.1, 1, 10, 100, 200 Pmol/L)
were investigated for their inhibitory effects 
on hepatic CYP2C9 and CYP3A4 catalytic
activities in human liver microsomes (He 
and Edeki, 2004). Tolbutamide 4-
methylhydroxylation and testosterone 6-
beta-hydroxylation were used as index 
reactions of CYP2C9 or CYP3A4 catalytic
activities, respectively. The metabolites of
both reactions were measured by high-
performance liquid chromatography and 
used as indicators of whether enzymes were 
inhibited or unaffected by these agents. 
Ginsenoside Rd had significant inhibitory 
potency on both CYP2C9- and CYP3A4-
mediated index reactions with IC(50) values 
of 105 and 62 Pmol/L, respectively.
Ginsenosides Rb1, Rb2, and Rc had limited
inhibitory activities on both enzyme reaction 
systems. It is concluded by the authors that 
ginsenoside Rd have the potential to interact 
with conventional medicines that are 
metabolized by CYP2C9 and CYP3A4 in
vivo.
P-glycoprotein (Pgp) is a 170 kDa 
phosphorylated glycoprotein encoded by 
human MDR1 gene. It is responsible for the 
systemic disposition of numerous
structurally and pharmacologically unrelated 
lipophilic and amphipathic drugs, 
carcinogens, toxins, and other xenobiotics in 
many organs, such as the intestine, liver, 
kidney, and brain. By using an ATPase 
assay, purified Pgp protein or intact Pgp-
expressing cells, and proper probe 
substrates, several ginsenosides have been 
found to be inhibitors of Pgp (Zhou et al., 
2004). The inhibition of Pgp activity by 
these constituents of different ginseng
species could result in altered absorption 
and bioavailability of drugs that are Pgp 
substrates.
To evaluate the interactions between
American ginseng and warfarin, a 
randomized, double-blind, placebo-
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controlled trial has been performed (Yuan et 
al., 2004). In a 4-week study, 20 young, 
healthy volunteers received warfarin for 3 
days during weeks 1 and 4. Beginning in 
week 2, subjects were assigned to receive 
either American ginseng (Panax
quinquefolius, 0.5 g powdered ground root. 
Using HPLC total ginsenoside content was 
5.19%; Rb1 1.93%; Rb2 0.2%; Rc 0.61%; 
Rd 0.42%; Re 1.68%; Rg1 0.35%) or 
placebo. The peak International normalized
ratio (prothrombin time test-control ratio)
statistically significantly decreased after 2 
weeks of ginseng administration compared
with placebo (difference between ginseng 
and placebo, -0.19 [95% CI, -0.36 to -0.07]; 
P = 0.0012). The International normalized
ratio area under the curve (AUC), peak 
plasma warfarin level, and warfarin AUC 
were also statistically significantly reduced 
in the ginseng group as compared with the 
placebo group. Peak International 
normalized ratio and peak plasma warfarin
level were positively correlated. The authors 
conclude that American ginseng reduces the 
anticoagulant effect of warfarin. And when 
prescribing warfarin, physicians should ask 
patients about ginseng use. 
The aim of another study was to investigate 
the effect of St John's wort and ginseng on 
the pharmacokinetics and 
pharmacodynamics of warfarin (Jiang et al., 
2004). Warfarin is a racemic mixture of the 
R- and S-enantiomers. Most of the 
anticoagulant activity of warfarin is 
attributable to S-warfarin but the activity is 
as well influenced by the hepatic levels of 
vitamin K. CYP2C9 is the principal enzyme
responsible for S-warfarin metabolism. The 
ginseng used in the study was the brand 
Golden Glow (Korean ginseng, each capsule 
containing extract equivalent to 0.5 g Panax
ginseng root and 8.93 mg ginsenosides as 
ginsenoside Rg1). It was an open-label, 
three-way randomized crossover study in 12 
healthy male subjects, who received a single 
25-mg dose of warfarin alone or after 14 
days pretreatment with St John's wort, or 7 
days pretreatment with ginseng. Dosing with 
St John's wort or ginseng was continued for 
7 days after administration of the warfarin 
dose. Platelet aggregation, international
normalized ratio (INR) of prothrombin time,
warfarin enantiomer protein binding, 
warfarin enantiomer concentrations in 
plasma and S-7-hydroxywarfarin 
concentration in urine were measured. INR 
and platelet aggregation were not affected 
by treatment with St John's wort or ginseng. 
The apparent clearances of S-warfarin after 
warfarin alone or with St John's wort or 
ginseng were, respectively, 198 +/- 38 ml
h(-1), 270 +/- 44 ml h(-1) and 220 +/- 29 ml
h(-1). The respective apparent clearances of 
R-warfarin were 110 +/- 25 ml h(-1), 142 
+/- 29 ml h(-1) and 119 +/- 20 ml h(-1). St 
John's wort and ginseng did not affect the 
apparent volumes of distribution or protein 
binding of warfarin enantiomers. The 
authors conclude that St John's wort 
significantly induced the apparent clearance 
of both S-warfarin and R-warfarin, which in 
turn resulted in a significant reduction in the 
pharmacological effect of rac-warfarin. 
Coadministration of warfarin with ginseng 
did not affect the pharmacokinetics or 
pharmacodynamics of either S-warfarin or 
R-warfarin (Jiang et al., 2004). 
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Conclusions and possible future 
research areas 
A total of 35 clinical studies were reviewed. 
Of these 23 studies showed a positive effect 
(or not a negative effect e.g. induction or 
interaction) of ginseng (Panax species) on 
one or more of the measured effect 
parameters and 12 studies showed no 
significant effect (or did show an ability to 
interact with warfarin). The design of the 
studies was of very different quality but 
most of them were randomized, placebo-
controlled and blinded, and a few were 
cohort studies. 
Eight studies investigating the possible 
effects of ginseng on cognitive performance
and mood were included. Three studies 
showed improvement of cognitive 
performance tests, particularly improved
accuracy and speed but with no effects on 
mood after a single dose of 400 or 200 mg
G115, standardized ginseng extract. One 
study reported improved general health after 
G115 supplement twice daily for 12 weeks. 
One study showed improvement of health-
related-quality of life after 4 weeks 
treatment with 200 mg G115 per day but 
after 8 weeks of treatment no significant 
difference compared to placebo was
observed. Three studies showed no 
significant effects of long term ginseng 
supplement on memory tests or mood.
Five studies of the possible effects of Panax
ginseng (three using G115) on physical 
performance was included. Only one of 
these showed positive effects of 100 mg 
G115 twice daily for three months, on 
several lung function tests in patients with 
chronic obstructive pulmonary disease. 
Two of three studies showed positive effects
of ginseng supplement in women with
menopausal symptoms.
Eight studies performed by a group of 
Canadian researchers, aimed to investigate 
the possible glucose lowering effect of 
ginseng. Six of these yielded positive results 
in favour of American ginseng (Panax
quinquefolius L.) compared with placebo. 
Generally the positive effects observed were 
lower plasma glucose levels after a glucose 
challenge test in both healthy subjects and 
type 2 diabetic patients after a single dose of 
American ginseng. The opposite effect on 
plasma glucose were actually seen in one 
study after a single dose of P. ginseng and a 
specific batch of American ginseng did not 
have glucose lowering effect probably 
because of a lower or altered ginsenoside
profile. One of the studies was a long-term
study (8 weeks) and this study also found 
lower fasting blood glucose and reduced 
HbA1c in type 2 diabetic patients after intake 
of American ginseng compared to intake of 
placebo before each meal.
Furthermore has two clinical studies shown 
reduced risk of acute respiratory illness
during treatment with American ginseng, a 
cohort study has shown reduced risk of 
cancer when taking ginseng supplement and 
one randomized study has shown improved
recovery after gastric cancer operation after 
ginseng treatment compared with placebo
treatment. Treatment with Korean red 
ginseng has in two studies shown positive
effects on blood pressure and endothelial 
function in hypertensive patients. Korean 
red ginseng has also been found to have 
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positive effects on male sexual dysfunction.
And one study has indicated that Panax
ginseng has positive effects on lipid 
metabolism.
In vitro studies have indicated that some
ginsenosides may inhibit CYP2C9 and 
CYP3A4 and P-glycoprotein, and a clinical
study has not found that ginseng treatment
lead to an indiction of CYP3A4. One 
clinical study has shown interaction of 
American ginseng (Panax quinquefolius)
with warfarin but another clinical study 
using Panax ginseng has not found 
interaction with warfarin.
This summary of areas in which positive 
effects of ginseng have been obtained, 
indicate that an obvious future research area 
is the use of American ginseng in the 
treatment of type 2 diabetes. It can be 
speculated that ginseng supplement could 
reduce the need for other diabetic medicines
and postpone the point where insulin 
therapy is required in type 2 diabetic 
patients. Other possible areas where positive
effects could be expected are cancer, lung 
infections and perhaps hypertension. It is 
very difficult to conclude about the effects 
of ginseng on cognitive functions because 
these functions are a bit more difficult to 
measure exactly, but several studies does 
indicate improved test scores and general 
health after ginseng treatment. But in all of
the areas further studies are still needed to 
evaluate the possible positive effects of
ginseng.
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Ginseng has been used as an herbal remedy in Asia for thousands of 
years and it has been claimed effective in improving several disorders 
and general health functions including cancer, diabetes, cardiovas-
cular disorders, immune functions, vitality, sexual function, cognitive 
and physical performance. But early clinical trials (from before the 
mid 1990s) aimed to test the efficacy of ginseng used for any of the 
claimed indications have yielded contradictory results.
The aim of this review was to collect and report the results of more re-
cent clinical trials of ginseng (Panax species). We would like the review 
to allow identification of any possible interesting results or indications 
that deserve further investigation in the future.
The review indicates that an obvious future research area is the use of 
American ginseng (Panax quinquefolius) in the treatment of diabetes. 
Other possible areas where positive effects could be expected are can-
cer, lung infections and perhaps hypertension. But further studies are 
still needed to evaluate the possible clinical effects of ginseng.
